Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX).

Full DD Report for SNDX

You must become a subscriber to view this report.


Recent News from (NASDAQ: SNDX)

Syndax Pharmaceuticals, Inc. 2018 Q3 - Results - Earnings Call Slides
The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with their 2018 Q3 earnings Read more ...
Source: SeekingAlpha
Date: November, 06 2018 15:29
Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2018 Results - Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Q3 2018 Earnings Conference Call November 05, 2018, 04:30 PM ET Executives Melissa Forst - Argot Partners, VP Briggs Morrison - CEO Michael Metzger - President & COO Michael Meyers - Chief Medical Officer & Senior VP Peter Ordentlic...
Source: SeekingAlpha
Date: November, 05 2018 22:49
Syndax Pharmaceuticals beats by $0.08, beats on revenue
Syndax Pharmaceuticals (NASDAQ: SNDX ): Q3 GAAP EPS of -$0.68 beats by $0.08 . More news on: Syndax Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: November, 05 2018 16:06
Syndax Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Clinical and Business Update
WALTHAM, Mass. , Nov. 5, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the third quarter en...
Source: PR Newswire
Date: November, 05 2018 16:05
Syndax Pharmaceuticals Announces Presentations at the 60th American Society of Hematology Annual Meeting
WALTHAM, Mass. , Nov. 1, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company's Menin-MLLr program will be...
Source: PR Newswire
Date: November, 01 2018 16:09
Syndax to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 5, 2018
WALTHAM, Mass. , Oct. 29, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2018 finan...
Source: PR Newswire
Date: October, 29 2018 07:00
Syndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung Cancer
WALTHAM, Mass. , Oct. 25, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced it will provide an update on E2112, its NCI-s...
Source: PR Newswire
Date: October, 25 2018 16:05
Syndax to Present at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer
WALTHAM, Mass. , Sept. 5, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that data from the PD-(L)1 refractory non-sm...
Source: PR Newswire
Date: September, 05 2018 17:00
Syndax Announces Participation at Three Upcoming Investor Conferences
WALTHAM, Mass. , Aug. 28, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the management team will participa...
Source: PR Newswire
Date: August, 28 2018 07:00
New Research: Key Drivers of Growth for REGENXBIO, Syndax Pharmaceuticals, Rowan Companies, CTS, Basic Energy Services, and Impinj - Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of REGENXBIO Inc. (NASDAQ:RGNX), Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX),...
Source: GlobeNewswire
Date: August, 27 2018 08:15

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-146.406.616.8996.32270,044
2018-05-218.938.939.2298.6235589,248
2018-05-188.748.809.288.61665,690
2018-05-1711.088.6111.248.191,611,860
2018-05-1611.3511.1211.3510.97286,059

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-108,97116,43554.5847Short
2018-12-0716,63529,41856.5470Short
2018-12-0623,23640,99956.6746Short
2018-12-0417,43859,10429.5039Cover
2018-12-0317,18345,39337.8539Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SNDX.


About Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX)

Logo for Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $217,341,907 - 05/18/2018
  • Issue and Outstanding: 24,697,944 - 03/05/2018

 


Recent Filings from (NASDAQ: SNDX)

Filing Type: CT ORDERFiling Source: edgar
Filing Date: August, 29 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 08 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: August, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 20 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: June, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 25 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 10 2018

 

 


Daily Technical Chart for (NASDAQ: SNDX)

Daily Technical Chart for (NASDAQ: SNDX)


Stay tuned for daily updates and more on (NASDAQ: SNDX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: SNDX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SNDX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of SNDX and does not buy, sell, or trade any shares of SNDX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/